Literature DB >> 23770101

Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.

Nathalie Goemans1, Marleen van den Hauwe, Rosamund Wilson, Annelies van Impe, Katrijn Klingels, Gunnar Buyse.   

Abstract

In order to understand contemporary natural history of Duchenne muscular dystrophy (DMD), we report 6-minute walk distance (6MWD) and its change over time from a large single centre population of corticosteroid treated DMD boys. Sixty-five boys on daily corticosteroid treatment were identified with a mean (SD) age of 9.5 (2.3) years at first observation. 6MWD was described for 1year age groupings. In addition, changes in 6MWD at 1, 1.5 and 2years (±12weeks) of follow-up were evaluated. The same evaluations were applied to 6MWD data converted to percent predicted values based on the Geiger equation. 6MWD showed an increase from age group 4.5-5.5years to age group 6.5-7.5years, followed by a decline, which became precipitous from 12.5years onwards. From 15.5years, all boys were unable to perform the 6-min test. Changes in 6MWD demonstrated a mean (median, SD) decline of -43 (-14, 90) m at 1year (N=25, mean baseline age 9.5years), -64 (-56, 99) m at 1.5years (N=18, mean baseline age 9.6years), -125 (-106, 139) m at 2years (N=14, mean baseline age 10.0years). Conversion to percent predicted values showed the same pattern of evolution.This study provides data on the ambulatory capacity and its changes over time in a homogenous cohort of 65 DMD boys on daily corticosteroids. The variability, the age-related aspects and the slope of decline of the 6MWD should be considered in the design and interpretation of therapeutic trials in ambulant DMD patients.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  6-Min walk test; Ambulatory capacity; Corticosteroids; Disease evolution; Duchenne muscular dystrophy; Variability

Mesh:

Substances:

Year:  2013        PMID: 23770101     DOI: 10.1016/j.nmd.2013.05.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  27 in total

Review 1.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

2.  Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.

Authors:  Janelle L Lennie; John T Mondick; Marc R Gastonguay
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-01-20       Impact factor: 2.745

3.  Low-level dystrophin expression attenuating the dystrophinopathy phenotype.

Authors:  Megan A Waldrop; Felecia Gumienny; Saleh El Husayni; Diane E Frank; Robert B Weiss; Kevin M Flanigan
Journal:  Neuromuscul Disord       Date:  2017-11-23       Impact factor: 3.538

4.  Association of genetic mutations and loss of ambulation in childhood-onset dystrophinopathy.

Authors:  Gregory Haber; Kristin M Conway; Pangaja Paramsothy; Anindya Roy; Hobart Rogers; Xiang Ling; Nicholas Kozauer; Natalie Street; Paul A Romitti; Deborah J Fox; Han C Phan; Dennis Matthews; Emma Ciafaloni; Joyce Oleszek; Katherine A James; Maureen Galindo; Nedra Whitehead; Nicholas Johnson; Russell J Butterfield; Shree Pandya; Swamy Venkatesh; Venkatesh Atul Bhattaram
Journal:  Muscle Nerve       Date:  2020-11-17       Impact factor: 3.852

5.  Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years.

Authors:  Nathalie Goemans; Katrijn Klingels; Marleen van den Hauwe; Stefanie Boons; Liese Verstraete; Charlotte Peeters; Hilde Feys; Gunnar Buyse
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

6.  Age-related longitudinal changes in metabolic energy expenditure during walking in boys with Duchenne muscular dystrophy.

Authors:  Merel-Anne Brehm; Jiska C E Kempen; Anneke J van der Kooi; Imelda J M de Groot; Janneke C van den Bergen; Jan J G M Verschuuren; Erik H Niks; Jaap Harlaar
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

7.  Periodic sound-based 6-minute walk test forpatients with Duchenne muscular dystrophy:a preliminary study.

Authors:  Hitomi Nishizawa; Hirokazu Genno; Naoko Shiba; Akinori Nakamura
Journal:  J Phys Ther Sci       Date:  2015-11-30

Review 8.  Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy.

Authors:  Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Hum Genet       Date:  2016-08-20       Impact factor: 4.132

9.  Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests.

Authors:  Sarah P Sherlock; Yao Zhang; Michael Binks; Shannon Marraffino
Journal:  Biomark Med       Date:  2021-06-22       Impact factor: 2.851

10.  Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.

Authors:  Eugenio Mercuri; James Edward Signorovitch; Elyse Swallow; Jinlin Song; Susan J Ward
Journal:  Neuromuscul Disord       Date:  2016-05-27       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.